
Release date: 2024-08-23 17:57:53 Article From: Lucius Laos Recommended: 299
Alpelisib has demonstrated a unique efficacy against PIK3CA mutations in HR/HER2- advanced breast cancer, and the combination with fulvestrant further enhances the anti-tumor effect.
It is important to know the dosage and how to take Alpelisib to be effective in treatment.
The standard dose of Apelix is 300 mg, which is equivalent to taking two 150 mg film-coated tablets per day. It is recommended to take it once a day, preferably with a meal, to help improve the absorption of the drug.
Tablets should be swallowed whole, not chewed, crushed, or separated. If the tablet is found to be broken, cracked, or incomplete, it should be avoided.
Knowing how and how much to use Alpelisib can help ensure the best possible outcome. Patients should be aware of drug interactions before taking medication to avoid potential drug conflicts.
Understanding how apelix interacts with other drugs is critical to optimizing treatment options.
When used in combination with breast cancer resistance protein (BCRP) inhibitors, concentrations of Alpelisib may increase, increasing the risk of toxicity. BCRP inhibitors should be avoided while receiving Alpelisib, and if they cannot be avoided, an increase in adverse effects should be closely monitored.
Alpelisib, when used in combination with a CYP2C9 substrate such as warfarin, may reduce plasma concentrations of these drugs. Concentrations of CYP2C9 substrates need to be closely monitored to ensure that the drug effect is not affected.
Understanding drug interactions is critical to effective medication. Next, we will introduce the common adverse effects of Alpelisib and how to manage them.
Alpelisib may trigger a number of adverse effects that require close attention and appropriate management. The following are some common adverse reactions and recommendations for their treatment.
The use of drugs may cause you to feel unusually tired or weak, affecting your daily activities and quality of life. Long-term fatigue may require treatment adjustments.
Medications can cause hemoglobin levels to drop, triggering symptoms of anemia, such as fatigue, dizziness or shortness of breath. Blood markers need to be monitored to prevent severe anaemia.
Understanding the possible adverse effects of a drug is key to its use.
[Warm tips] Store the drug in a dry and cool place, avoid high temperature and humidity, and keep the drug properties stable.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3492025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3502025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643